908 Devices Inc. revenue
908 Devices Inc.'s revenue was $56.2m in fiscal 2025, up 17.7% on the year before. Since fiscal 2020 ($26.9m) it has grown at a compound 15.9% a year. Over the last twelve months it was $60.8m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Products | $43.3M | ▲ 21.8% |
| Device Sales | $36.7M | ▲ 15.7% |
| Recurring | $19.4M | ▲ 21.9% |
| Services | $12.9M | ▲ 5.7% |
| Contract | $117,000 | ▼ 11.4% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $41.2M | 73.4% | ▲ 15.7% |
| EMEA | $10.4M | 18.6% | ▲ 14.2% |
| Asia Pacific | $3M | 5.3% | ▲ 42.5% |
| Americas Other | $1.5M | 2.7% | ▲ 76.7% |
From 908 Devices Inc.'s 10-K filed March 9, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| 908 Devices Inc. | $60.8m | 13.4% | 7.5% |
| Precipio, Inc. | $60.8m | 29.5% | 43.6% |
| Champions Oncology, Inc. | $60.7m | 6.7% | 4.8% |
| Personalis, Inc. | $69.7m | -13.3% | 1.2% |
| Exagen Inc. | $71.1m | 20.8% | 10.3% |
| Burning Rock Biotech Ltd | $75.1m | 4.7% | — |
Compare with peers
- Precipio, Inc. revenue
- Champions Oncology, Inc. revenue
- Personalis, Inc. revenue
- Exagen Inc. revenue
- Burning Rock Biotech Ltd revenue
Head to head: MASS vs PRPOCSBR vs MASSMASS vs PSNL
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies